1151893-81-0

Basic information

• Product Name: (S)-2-(2-(5-chloro-N-(4-(5-((5-chlorothiophene-2-carboxamido)methyl)-2-oxooxazolidin-3-yl)phenyl)thiophene-2-carboxamido)ethoxy)acetic acid
• Synonyms: (S)-2-(2-(5-chloro-N-(4-(5-((5-chlorothiophene-2-carboxamido)methyl)-2-oxooxazolidin-3-yl)phenyl)thiophene-2-carboxamido)ethoxy)acetic acid;2-[2-[[(5-Chloro-2-thienyl)carbonyl][4-[(5S)-5-[[[(5-chloro-2-thienyl)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]phenyl]amino]ethoxy]acetic Acid
• CAS NO: 1151893-81-0
• Molecular Formula: C₂₄H₂₁Cl₂N₃O₇S₂
• Molecular Weight: 598.47544
• EINECS: -0
• Mol File: 1151893-81-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 843.9±65.0 °C(Predicted)
• Appearance: /
• Density: 1.542±0.06 g/cm3(Predicted)
• PKA: 3.37±0.10(Predicted)
• CAS DataBase Reference: (S)-2-(2-(5-chloro-N-(4-(5-((5-chlorothiophene-2-carboxamido)methyl)-2-oxooxazolidin-3-yl)phenyl)thiophene-2-carboxamido)ethoxy)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(2-(5-chloro-N-(4-(5-((5-chlorothiophene-2-carboxamido)methyl)-2-oxooxazolidin-3-yl)phenyl)thiophene-2-carboxamido)ethoxy)acetic acid(1151893-81-0)
• EPA Substance Registry System: (S)-2-(2-(5-chloro-N-(4-(5-((5-chlorothiophene-2-carboxamido)methyl)-2-oxooxazolidin-3-yl)phenyl)thiophene-2-carboxamido)ethoxy)acetic acid(1151893-81-0)

Safety Data

• Hazardous Substances Data: 1151893-81-0(Hazardous Substances Data)

Usage

General Description

The chemical compound "(S)-2-(2-(5-chloro-N-(4-(5-((5-chlorothiophene-2-carboxamido)methyl)-2-oxooxazolidin-3-yl)phenyl)thiophene-2-carboxamido)ethoxy)acetic acid" is a complex molecule with a long and specific structure. It contains several functional groups including chloro, carboxamido, thiophene, oxazolidin, and acetic acid. The compound appears to be a combination of different structural elements, and it likely exhibits a range of chemical and biological activities due to the diversity of its components. The presence of chloro and carboxamido groups suggests the potential for interactions with biological systems, and the overall structure may be relevant in pharmaceutical or medicinal chemistry as a potential drug candidate or pharmacological tool.

Upstream product

• 42518-98-9 5-chlorothiophene-2-carbonyl chloride 
• 931204-39-6 2-[2-({4-[(5S)-5-{[(5-chlorothiophen-2-yl)formamido]methyl}-2-oxo-1,3-oxazolidin-3-yl]phenyl}amino)ethoxy]acetic acid 
• 366789-02-8 Rivaroxaban 
• 482308-02-1 N-{[(5S)-3-(4-aminophenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}-5-chloro-2-thiophenecarboxamide 
• 1082937-62-9 C₂₀H₂₂ClN₃O₅S 
• 1082937-60-7 C₁₅H₂₁N₃O₄ 
• 19298-14-7 4-di[(2-hydroxyethyl)amino]-aniline 
• 24065-33-6 5-Chlorothiophene-2-carboxylic acid 
• 931117-61-2 2-({4-[(5S)-5-({[(5-chloro-2-thienyl)carbonyl]amino}methyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}-amino)ethoxyacetic acid hydrochloride 

Relevant articles and documents

A [...] related substance diamine synthesis method

The invention relates to a rivaroxaban related substance diamine which can be used as a reference substance to research and control rivaroxaban. The preparation method is simple, and the raw materials are easily available. The structural formula of the diamine is shown as follows: FORMULA shown in the description and the formula is C25H24CL2N4O4S2, and the molecular weight is 610.5. The rivaroxaban related substance diamine provided by the invention can be used as a reference substance for monitoring impurities of the rivaroxaban. The synthetic method for the rivaroxaban related substance diamine provided by the invention is simple to operate, has excellent practicality, and can bringrelatively good economic and social benefits.

Rivaroxaban impurities and preparing method and application thereof

The invention discloses rivaroxaban impurities. The rivaroxaban impurities include the rivaroxaban impurity 6, the rivaroxaban impurity 10, the rivaroxaban impurity 11 and the rivaroxaban impurity 12; in addition, the invention discloses a preparing method and application of the rivaroxaban impurities. By means of the rivaroxaban impurities and the preparing method thereof, the basis is consolidated for rivaroxaban midbodies and raw material medicine and quality researching of compositions of the rivaroxaban impurities. The structural formula is shown in the specification.